Hmet-G 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The combination of these two agents offers complementary mechanisms of action, providing effective control of blood sugar levels in patients inadequately managed by diet and exercise alone. Hmet-G 1 Tablet PR is indicated for adult patients with type 2 diabetes who require dual therapy to achieve target glycemic levels. It should be used alongside lifestyle modifications such as diet and physical activity. The extended-release formulation allows for once-daily dosing, improving patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is primarily associated with Glimepiride. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. This medication should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.